Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154


Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.

Wu MS, Tan SC, Xiong T.

Aliment Pharmacol Ther. 2013 Jul;38(2):190-201. doi: 10.1111/apt.12349. Epub 2013 May 29.


The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.

Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.

Aliment Pharmacol Ther. 2013 Apr;37(8):810-8. doi: 10.1111/apt.12270. Epub 2013 Mar 4.


Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.

Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.

Aliment Pharmacol Ther. 2013 Nov;38(10):1303-11. doi: 10.1111/apt.12504. Epub 2013 Sep 30.


Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.

Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN.

Aliment Pharmacol Ther. 2009 Jun 15;29(12):1261-72. doi: 10.1111/j.1365-2036.2009.04013.x. Epub 2009 Apr 8.


Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.

Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN.

Aliment Pharmacol Ther. 2009 Apr 1;29(7):742-54. doi: 10.1111/j.1365-2036.2009.03954.x. Epub 2009 Feb 7.


Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.

Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, Peura D.

Aliment Pharmacol Ther. 2009 Apr 1;29(7):731-41. doi: 10.1111/j.1365-2036.2009.03933.x.


Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002095. doi: 10.1002/14651858.CD002095.pub4. Review. Update in: Cochrane Database Syst Rev. 2013;5:CD002095.


Review of esomeprazole in the treatment of acid disorders.

Johnson DA.

Expert Opin Pharmacother. 2003 Feb;4(2):253-64. Review.


Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.

Bytzer P, van Zanten SV, Mattsson H, Wernersson B.

Aliment Pharmacol Ther. 2012 Oct;36(7):635-43. doi: 10.1111/apt.12007. Epub 2012 Aug 1.


Esomeprazole: a review of its use in the management of acid-related disorders.

Scott LJ, Dunn CJ, Mallarkey G, Sharpe M.

Drugs. 2002;62(10):1503-38. Review.


Obesity does not affect treatment outcomes with proton pump inhibitors.

Sharma P, Vakil N, Monyak JT, Silberg DG.

J Clin Gastroenterol. 2013 Sep;47(8):672-7. doi: 10.1097/MCG.0b013e31827e46be.


Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.

Croxtall JD, Scott LJ.

Drugs. 2010 Aug 20;70(12):1593-601. doi: 10.2165/11295960-000000000-00000. Review.


Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.

Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, Damico D, Hamelin B.

Am J Gastroenterol. 2001 Jan;96(1):27-34. Erratum in: Am J Gastroenterol 2001 Mar;96(3):942.


Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.

Gold BD, Pilmer B, KierkuĊ› J, Hunt B, Perez MC, Gremse D.

Dig Dis Sci. 2017 Nov;62(11):3059-3068. doi: 10.1007/s10620-017-4743-3. Epub 2017 Sep 15.


Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.

Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN.

Aliment Pharmacol Ther. 2009 Nov 1;30(9):895-907. doi: 10.1111/j.1365-2036.2009.04119.x. Epub 2009 Aug 14.


Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.

Sharma P, Johnson DA, Monyak JT, Illueca M.

Aliment Pharmacol Ther. 2011 Aug;34(4):487-93. doi: 10.1111/j.1365-2036.2011.04736.x. Epub 2011 Jun 20.


Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.

Abel C, Desilets AR, Willett K.

Ann Pharmacother. 2010 May;44(5):871-7. doi: 10.1345/aph.1M685. Epub 2010 Apr 6. Review.


Supplemental Content

Support Center